Faculty ProfilesDaniel Adelman, MD
400 Parnassus Avenue
San Francisco, CA 94117
Education and Training
|Location||Degree or Training||Specialty||Date|
|University of California Davis||M.D.||School of Medicine||1983|
Recent Articles (41)
Mahadev S, Murray JA, Wu TT, Chandan VS, Torbenson MS, Kelly CP, Maki M, Green PH, Adelman D, Lebwohl B. Factors associated with villus atrophy in symptomatic coeliac disease patients on a gluten-free diet. Aliment Pharmacol Ther. 2017 Apr; 45(8):1084-1093.
Garber ME, Saldanha A, Parker JS, Jones WD, Kaukinen K, Laurila K, Lähdeaho ML, Khatri P, Khosla C, Adelman DC, Mäki M. A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac Disease. Cell Mol Gastroenterol Hepatol. 2017 Jul; 4(1):1-17.
Murray JA, Kelly CP, Green PH, Marcantonio A, Wu TT, Mäki M, Adelman DC. No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients with Symptomatic Celiac Disease. Gastroenterology. 2016 Nov 15.
Lähdeaho ML, Kaukinen K, Laurila K, Vuotikka P, Koivurova OP, Kärjä-Lahdensuu T, Marcantonio A, Adelman DC, Mäki M. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology. 2014 Jun; 146(7):1649-58.
Siegel M, Garber ME, Spencer AG, Botwick W, Kumar P, Williams RN, Kozuka K, Shreeniwas R, Pratha V, Adelman DC. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig Dis Sci. 2012 Feb; 57(2):440-50.
Krug LM, Crawford J, Ettinger DS, Shapiro GI, Spigel D, Reiman T, Temel JS, Michelson GC, Young DY, Hoch U, Adelman DC. Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. J Thorac Oncol. 2011 Feb; 6(2):384-6.
Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, Adelman DC. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res. 2010 Apr 1; 16(7):2167-75.
Corren J, Shapiro G, Reimann J, Deniz Y, Wong D, Adelman D, Togias A. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J Allergy Clin Immunol. 2008 Feb; 121(2):506-11.
Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs. 2008 Feb; 26(1):59-65.
Corren J, Diaz-Sanchez D, Saxon A, Deniz Y, Reimann J, Sinclair D, Davancaze T, Adelman D. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. Ann Allergy Asthma Immunol. 2004 Sep; 93(3):243-8.
Kereiakes DJ, Szyniszewski AM, Wahr D, Herrmann HC, Simon DI, Rogers C, Kramer P, Shear W, Yeung AC, Shunk KA, Chou TM, Popma J, Fitzgerald P, Carroll TE, Forer D, Adelman DC. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results. Circulation. 2003 Sep 16; 108(11):1310-5.
Chou TM, Woodburn KW, Cheong WF, Lacy SA, Sudhir K, Adelman DC, Wahr D. Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium. Catheter Cardiovasc Interv. 2002 Nov; 57(3):387-94.
Chen Z, Woodburn KW, Shi C, Adelman DC, Rogers C, Simon DI. Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells. Arterioscler Thromb Vasc Biol. 2001 May; 21(5):759-64.
Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S, Breed J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001 Feb 1; 19(3):851-6.
Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001 Feb 1; 19(3):843-50.
Rockson SG, Kramer P, Razavi M, Szuba A, Filardo S, Fitzgerald P, Cooke JP, Yousuf S, DeVault AR, Renschler MF, Adelman DC. Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin). Circulation. 2000 Nov 7; 102(19):2322-4.
Shearer WT, Abramson SL, Adelman DC, Corn B, Cunningham-Rundles C, Kishiyama JL, Richmond W, Shames RS, Sperber K, Stiehm ER, Valacer DJ. Letter to the editor regarding the use of intravenous immunoglobulin (IVIG) in asthma. Clin Immunol. 1999 Nov; 93(2):184-6.
Fahy JV, Cockcroft DW, Boulet LP, Wong HH, Deschesnes F, Davis EE, Ruppel J, Su JQ, Adelman DC. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med. 1999 Sep; 160(3):1023-7.
Saini SS, MacGlashan DW, Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, Bochner BS. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999 May 1; 162(9):5624-30.
Kishiyama JL, Valacer D, Cunningham-Rundles C, Sperber K, Richmond GW, Abramson S, Glovsky M, Stiehm R, Stocks J, Rosenberg L, Shames RS, Corn B, Shearer WT, Bacot B, DiMaio M, Tonetta S, Adelman DC. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol. 1999 May; 91(2):126-33.
Shames RS, Heilbron DC, Janson SL, Kishiyama JL, Au DS, Adelman DC. Clinical differences among women with and without self-reported perimenstrual asthma. Ann Allergy Asthma Immunol. 1998 Jul; 81(1):65-72.
Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ, Fick RB, Adelman DC. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol. 1997 Jul; 100(1):110-21.
MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997 Feb 1; 158(3):1438-45.
Shearer WT, Adelman DC, Huston DP, Engler RJ, Gupta S, Ledford DK, Lopez M, Du Buske LM. Core content outline for clinical and laboratory immunology. AAAI Training Program Directors' Committee. J Allergy Clin Immunol. 1994 Dec; 94(6 Pt 1):933-41.
Hassner A, Lau MS, Goetzl EJ, Adelman DC. Isotype-specific regulation of human lymphocyte production of immunoglobulins by sustained exposure to vasoactive intestinal peptide. J Allergy Clin Immunol. 1993 Dec; 92(6):891-901.
Adelman DC, Yen TY, Cumberland WG, Sidell N, Saxon A. 13-cis retinoic acid enhances in vivo B-lymphocyte differentiation in patients with common variable immunodeficiency. J Allergy Clin Immunol. 1991 Nov; 88(5):705-12.
Goetzl EJ, Hassner A, Cheng PP, Robichon A, Adelman DC, Sreedharan SP. Molecular characteristics of the cellular receptor for vasoactive intestinal peptide. Trans Assoc Am Physicians. 1991; 104:54-61.
Adelman DC, Matsuda T, Hirano T, Kishimoto T, Saxon A. Elevated serum interleukin-6 associated with a failure in B cell differentiation in common variable immunodeficiency. J Allergy Clin Immunol. 1990 Oct; 86(4 Pt 1):512-21.
Sherr E, Adelman DC, Saxon A, Gilly M, Wall R, Sidell N. Retinoic acid induces the differentiation of B cell hybridomas from patients with common variable immunodeficiency. J Exp Med. 1988 Jul 1; 168(1):55-71.